In a challenging market environment, 4D Molecular Therapeutics (FDMT) stock has reached a new 52-week low, dipping to $4.48, bringing its market capitalization to $210 million. The biotech company, known for its pioneering gene therapy techniques,
FDMT stock touches 52-week low at $4.48 amid market challenges
view original post